Multiomics in cancer immunotherapy

Immunotherapy for cancer has rapidly progressed in recent years with immune checkpoint inhibitors, antibody therapeutics, and CAR-T-based treatments now well established as options for cancer patients. The molecular, cellular, and systemic response to immunotherapy is incredibly complex, and patient immune responses can vary significantly. Multi-omic studies integrate genomic, transcriptomic, and proteomic data, often using computational and network biology to interpret the “big data” generated by these techniques. Applying multi-omics to clinical data can identify new biomarkers with the aim of targeting immunotherapies to the individual patient. This holistic approach leads to a more complete understanding of the mechanisms behind immunotherapy and has great potential for improving patient outcomes.

In this webinar we are pleased to host an interdisciplinary trio of speakers with clinical, basic research, and computational backgrounds. Samra Turajlic (The Francis Crick Institute), Rong Fan (Yale University), and Christina Leslie (Memorial Sloan Kettering Cancer Center) will speak about the advances and challenges in their research using multi-omics.

Samra Turajlic
Group Leader, Francis Crick Institute
Consultant Medical Oncologist, the Royal Marsden
NHS Foundation Trust

Rong Fan
Professor of Biomedical Engineering
Yale University

Christina Leslie
Member
Computational and Systems Biology Program
Memorial Sloan Kettering Cancer Center